Construction Business Review Conferences
Southeast Asia's biologics industry is entering a new phase of growth, driven by increasing healthcare demand, expanding biopharma capabilities and greater investment in biologics R&D, development and local manufacturing. Across the region, companies are strengthening capabilities to bring biologic medicines from early-stage research through clinical development, production and ultimately to patients. Vietnam is emerging as an important part of this evolving ecosystem. The country is working to strengthen its pharmaceutical and biotechnology capabilities, including biologics, biosimilars and vaccines, while encouraging technology transfer, local production and greater collaboration with regional and international partners. Together with established and growing biopharma markets across Singapore, Thailand, Malaysia, Indonesia and the wider Southeast Asian region, this is creating new opportunities across the biologics value chain.
Asia is becoming an increasingly important hub for sterile pharmaceutical and biopharmaceutical manufacturing, driven by the growth of biologics, vaccines, complex injectables and other high-value sterile medicines. Across the region, manufacturers are investing in advanced aseptic processing, barrier technologies, automation and flexible fill-finish capabilities to strengthen sterility assurance, manufacturing efficiency and supply resilience.
Genome editing is rapidly transforming the possibilities of modern medicine, enabling scientists to precisely modify DNA and RNA and opening new approaches to treating genetic disorders, cancer, infectious diseases and other complex conditions. Across Asia-Pacific, advances in CRISPR-Cas systems, base and prime editing, functional genomics, cell engineering and novel delivery technologies are accelerating the journey from fundamental research towards therapeutic development.
Hospitals across Asia are entering a new era of automation. Rising patient demand, workforce pressures and increasingly complex healthcare operations are accelerating investment in artificial intelligence, robotics, pharmacy automation, smart logistics, connected infrastructure and intelligent hospital systems. From advanced healthcare markets to rapidly expanding hospital networks, automation is becoming an important part of how hospitals across the region improve efficiency, patient safety and workforce productivity.
Asia's vaccine industry is entering a new phase of growth, driven by investment in next-generation vaccine technologies, manufacturing capacity and regional vaccine security. Across the region, this momentum is already taking shape — from Thailand's efforts to strengthen domestic vaccine manufacturing and technology transfer, to new and expanded vaccine manufacturing capabilities in Singapore and South Korea. Connexius Vaccines Asia Conference 2027, taking place on 23–24 June 2027 in Bangkok, Thailand, will bring together vaccine developers, manufacturers, biopharma leaders, regulators, government agencies and technology providers from across Asia.
South Korea has established itself as one of the world's leading biopharmaceutical manufacturing hubs, supported by a strong ecosystem of biologics developers, manufacturers and CDMOs. Continued investment from major players including Samsung Biologics, Celltrion and LOTTE BIOLOGICS is further expanding the country's manufacturing capabilities and strengthening Korea's position in the global biologics supply chain. This momentum is being supported by significant capacity expansion and next-generation manufacturing investments. Samsung Biologics' Plant 5 has added 180,000 litres of manufacturing capacity in Songdo, while Celltrion has announced further investment in new drug-substance facilities.
Analytica China is a spin-off exhibition of analytica, the International Trade Fair for Laboratory Technology, Analysis, Biotechnology and Diagnostics, addresses one of the industry's most important growth markets in Asia, i.e. China. Since its first edition in Shanghai, China in 2002, analytica China has become the biggest trade fair in China even in Asia. The exhibition is held every two years where the latest technologies and products will be displayed. Meanwhile, the concurrent technical conferences are the focuses of industry players as well.
Future Healthcare Investment Market (FHIM) is a long-term, year-round, invitation-only platform for senior decision-makers, connecting China and EMEA across healthcare innovation, healthcare services and investment. Built on the combined strengths of IPEM, HBI and a strong China-based network spanning government, healthcare institutions, investors, industry leaders and innovation partners, FHIM serves as a trusted bridge between two of the world's most dynamic healthcare ecosystems.
Precision Medicine Asia 2026, a two-day conference scheduled for October 21-22, 2026, in Taiwan. This exceptional event will gather top experts, innovators, and industry leaders to explore the transformative possibilities of precision medicine and drug discovery in Asia. Uncover the extraordinary potential of precision medicine at this year’s annual conference, where tailored treatments, based on genetics, environment, and lifestyle factors, take the spotlight. This dynamic programme is featuring keynote presentations, panel discussions and poster sessions, all designed to showcase the latest innovations and practical applications in precision medicine area.
Precision Medicine Asia 2026, a two-day conference scheduled for October 21-22, 2026, in Taiwan. This exceptional event will gather top experts, innovators, and industry leaders to explore the transformative possibilities of precision medicine and drug discovery in Asia. Uncover the extraordinary potential of precision medicine at this year’s annual conference, where tailored treatments, based on genetics, environment, and lifestyle factors, take the spotlight. This dynamic programme is featuring keynote presentations, panel discussions and poster sessions, all designed to showcase the latest innovations and practical applications in precision medicine area.
